nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2012 | Original Article

¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy

verfasst von: Daniel C. Bortot, Bárbara J. Amorim, Glaucia C. Oki, Sérgio B. Gapski, Allan O. Santos, Mariana C. L. Lima, Elba C. S. C. Etchebehere, Marycel F. Barboza, Jair Mengatti, Celso Dario Ramos

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bone scintigraphy (BS) has been used extensively for many years for the diagnosis of bone metastases despite its low specificity and significant rate of equivocal lesions. ¹⁸F-Fluoride PET/CT has been proven to have a high sensitivity and specificity in the detection of malignant bone lesions, but its effectiveness in patients with inconclusive lesions on BS is not well documented. This study evaluated the ability of ¹⁸F-fluoride PET/CT to exclude bone metastases in patients with various malignant primary tumours and nonspecific findings on BS.

Methods

We prospectively studied 42 patients (34–88 years of age, 26 women) with different types of tumour. All patients had BS performed for staging or restaging purposes but with inconclusive findings. All patients underwent ¹⁸F-fluoride PET/CT. All abnormalities identified on BS images were visually compared with their appearance on the PET/CT images.

Results

All the 96 inconclusive lesions found on BS images of the 42 patients were identified on PET/CT images. ¹⁸F-Fluoride PET/CT correctly excluded bone metastases in 23 patients (68 lesions). Of 19 patients (28 lesions) classified by PET/CT as having metastases, 3 (5 lesions) were finally classified as free of bone metastases on follow-up. The sensitivity, specificity, and positive and negative predictive values of ¹⁸F-fluoride PET/CT were, respectively, 100 %, 88 %, 84 % and 100 % for the identification of patients with metastases (patient analysis) and 100 %, 82 % and 100 % for the identification of metastatic lesions (lesion analysis).

Conclusion

The factors that make BS inconclusive do not affect ¹⁸F-fluoride PET/CT which shows a high sensitivity and negative predictive value for excluding bone metastases even in patients with inconclusive conventional BS.

Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999;79(9-10):1443–7. doi:10.1038/sj.bjc.6690230.PubMedCrossRef

Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging. 2011;55(4):374–410.PubMed

Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun. 2010;31(7):659–65. doi:10.1097/MNM.0b013e3283399107.PubMed

Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001;31(1):50–61.PubMedCrossRef

Silberstein EB, Saenger EL, Tofe AJ, Alexander Jr GW, Park HM. Imaging of bone metastases with 99mTc-Sn-EHDP (diphosphonate), 18F, and skeletal radiography. A comparison of sensitivity. Radiology. 1973;107(3):551–5.PubMed

Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332–4.PubMed

Picchio M, Giovannini E, Messa C. The role of PET/computed tomography scan in the management of prostate cancer. Curr Opin Urol. 2011;21(3):230–6. doi:10.1097/MOU.0b013e328344e556.PubMedCrossRef

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49(1):68–78. doi:10.2967/jnumed.106.037200.PubMedCrossRef

Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31(1):28–49.PubMedCrossRef

10.

Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50(1):128–39. doi:10.1016/j.bone.2011.09.053.PubMedCrossRef

11.

Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38(12):1970–6.PubMed

12.

Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35(2):135–42. doi:10.1053/j.semnuclmed.2004.11.005.PubMedCrossRef

13.

Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45(2):272–8.PubMed

14.

Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32(3):168–76. doi:10.1097/MNM.0b013e3283412ef5.PubMedCrossRef

15.

Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31(7):637–45. doi:10.1097/MNM.0b013e3283399120.PubMed

16.

Mattsson S, Soderberg M. Radiation dose management in CT, SPECT/CT and PET/CT techniques. Radiat Prot Dosim. 2011;147(1-2):13–21. doi:10.1093/rpd/ncr261.CrossRef

17.

Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, Hernandez-Maraver D, Coya J, Martin-Curto L, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47(10):1643–8.PubMed

18.

Pfluger T, Melzer HI, Schneider V, La Fougere C, Coppenrath E, Berking C, et al. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging. 2011;38(5):822–31. doi:10.1007/s00259-010-1702-z.PubMedCrossRef

Titel: 18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy
verfasst von: Daniel C. Bortot
Bárbara J. Amorim
Glaucia C. Oki
Sérgio B. Gapski
Allan O. Santos
Mariana C. L. Lima
Elba C. S. C. Etchebehere
Marycel F. Barboza
Jair Mengatti
Celso Dario Ramos
Publikationsdatum: 01.11.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2195-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2012

3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy

SPECT/CT imaging in 99mTc-HSA-DTPA gastrointestinal bleeding scintigraphy to localize bleeding sites

Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects

Preoperative FDG PET/CT in breast cancer patients: where are we going?

Induction and repair of DNA double-strand breaks in blood lymphocytes of patients undergoing 18F-FDG PET/CT examinations

Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model